We can’t show the full text here under this license.
Once-weekly dulaglutide’s effects on blood sugar levels in patients by gender, diabetes duration, and starting HbA1c
Updated
Abstract
In a pooled analysis, patients treated with dulaglutide 1.5 mg showed an average reduction in of -1.26% for men and -1.33% for women after 6 months.
- Dulaglutide treatment produced consistent reductions in HbA1c across different gender groups and varying durations of diabetes.
- Patients with a higher baseline HbA1c (≥8.5%) experienced greater reductions in HbA1c compared to those with lower levels (<8.5%).
- Similar trends in reductions were observed in line with HbA1c changes.
- Body weight changes were generally comparable across different durations of diabetes and baseline HbA1c subgroups, with women experiencing slightly more favorable outcomes.
- The incidence and rate of hypoglycaemia were lower in patients with higher baseline HbA1c, although results varied in one specific study involving mealtime insulin.
Simplified
Key numbers
-1.26%
Reduction (Dulaglutide 1.5 mg)
LS mean reduction at 6 months for men receiving dulaglutide 1.5 mg.
-1.86%
Reduction (Dulaglutide 1.5 mg)
LS mean reduction at 6 months for patients with baseline ≥8.5%.
5470
Total Patients Analyzed
Total number of patients across seven phase III studies.